Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hoechst-Roussel intermittent claudication consumer ad

Executive Summary

The firm began running its revised institutional television ad campaign for intermittent claudication the week of Dec. 23. The ad is scheduled to run two-three weeks. A similar ad appears in print media, including the New York Times, USA Today, and TV Guide. The television ad is a revision of a previous Hoechst ad to which FDA objected. FDA asserted that the earlier ad's emphasis on availability of a drug (the unspecified Trental) constituted an advertisement for a specific Rx drug ("The Pink Sheet" Oct. 21, T&G-5).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel